Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Liabilities: 2010-2025

Historic Total Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $131.4 million.

  • Catalyst Pharmaceuticals' Total Liabilities rose 18.27% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.4 million, marking a year-over-year increase of 18.27%. This contributed to the annual value of $123.8 million for FY2024, which is 50.52% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Total Liabilities is $131.4 million, which was up 13.35% from $115.9 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Total Liabilities ranged from a high of $131.4 million in Q3 2025 and a low of $18.6 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $97.7 million (2024), whereas its average is $97.2 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Total Liabilities declined by 0.12% in 2021 and then spiked by 175.00% in 2023.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Total Liabilities stood at $31.0 million in 2021, then surged by 142.95% to $75.2 million in 2022, then grew by 9.34% to $82.2 million in 2023, then surged by 50.52% to $123.8 million in 2024, then grew by 18.27% to $131.4 million in 2025.
  • Its Total Liabilities stands at $131.4 million for Q3 2025, versus $115.9 million for Q2 2025 and $114.6 million for Q1 2025.